pyrazines has been researched along with Granulocytic Leukemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arrate, MP; Ayers, GD; Boyd, KL; Fesik, SW; Fischer, MA; Fuller, L; Gorska, AE; Hogdal, LJ; Lee, T; Olejniczak, ET; Ramsey, HE; Savona, MR; Sensintaffar, J; Strickland, SA | 1 |
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Arai, S; Ichikawa, M; Imai, Y; Kataoka, K; Kumano, K; Kurokawa, M; Nakagawa, M; Nannya, Y; Nishimoto, N; Sato, T; Shimabe, M; Shinohara, A; Watanabe-Okochi, N; Yoshimi, A | 1 |
| Chen, WW; Huang, KK; Huang, M; Jiang, XJ; Meng, FY; Wang, Q; Wang, ZX; Wu, FQ; Zhou, HS | 1 |
| Huang, K; Li, Y; Ma, L; Nie, D; Wang, X; Wu, Y; Xiao, J; Xie, S; Yin, S | 1 |
| Ceder, R; Fadeel, B; Grafström, RC; Grandér, D; Hedenfalk, I; Heyman, M; Ottosson-Wadlund, A; Pokrovskaja, K; Preta, G; Robertson, JD; Söderhäll, S | 1 |
| Giles, FJ | 1 |
| Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S | 1 |
| Fu, YB; Meng, FY; Sun, QX; Xie, J; Zhou, GB | 1 |
| Bruserud, Ø; Gjertsen, BT; Kalland, KH; Olsnes, AM; Ryningen, A; Stordrange, L; Øyan, AM | 1 |
| Barasoain, I; Briand, C; de Ines, C; Garcia, P; Leynadier, D; Peyrot, V; Rener, GA; Temple, C | 1 |
| Adachi, M; Honma, Y; Hozumi, M; Nakai, S; Okabe-Kado, J; Sato, S; Tomoyasu, S; Tsuruoka, N | 1 |
1 review(s) available for pyrazines and Granulocytic Leukemia
| Article | Year |
|---|---|
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
12 other study(ies) available for pyrazines and Granulocytic Leukemia
| Article | Year |
|---|---|
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Indoles; K562 Cells; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Sulfonamides; THP-1 Cells; U937 Cells; Xenograft Model Antitumor Assays | 2018 |
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
Topics: Acute Disease; Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Core Binding Factor Alpha 2 Subunit; Cytoplasm; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; I-kappa B Kinase; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; NF-kappa B; Protein Binding; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid; Panobinostat; Pyrazines; Signal Transduction | 2011 |
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Gene Expression; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Valproic Acid | 2012 |
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Topics: Adolescent; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Boronic Acids; Bortezomib; Caspase 3; Child; Child, Preschool; Cytochromes c; fas Receptor; Fas-Associated Death Domain Protein; Gene Silencing; Humans; Jurkat Cells; Leukemia, Myeloid; Membrane Potential, Mitochondrial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transcriptome | 2013 |
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines | 2003 |
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2006 |
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Chemokines; Chemotaxis; DNA Replication; Female; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; NF-kappa B; Pyrazines; Receptors, Chemokine; Recombinant Fusion Proteins; T-Lymphocytes; Tumor Stem Cell Assay | 2007 |
Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
Topics: Animals; Antineoplastic Agents; Carbamates; Cell Cycle; Cell Line; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Mice; Microtubule Proteins; Microtubules; Pyrazines; Pyridines; Tumor Cells, Cultured | 1994 |
Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium; Cardiotonic Agents; Cell Differentiation; Drug Interactions; Drug Resistance; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Muramidase; Pyrazines; Quinolines; Stimulation, Chemical; Tretinoin; Tumor Cells, Cultured; Vincristine | 1996 |